OS and PFS in the R-FCM trial. (A) OS and PFS in the whole series. (B) OS and PFS in patients entering the rituximab maintenance-study phase. (C) PFS in patients grouped by MRD levels assessed in PB after induction evaluation. (D) PFS according to MRD levels in BM after induction evaluation. (E) PFS combining the degree of response and the MRD status in PB.